Ann: September 2022 Quarterly Update and Appendix 4C, page-18

They will be making a hell of a lot out of subsequent sales of equipment, instrumentation, software, training and servicing that derives from a successful outcome from our 12-mth collaborative R&D period. TFS will obviously financially benefit from their direct sales and sevices that incorporate OmnniCAR and PTX will derive royalties perhaps from TFS and licensing fees from each, lab, cancer centre and hospital for each and every manufacturing run. Obviously a supply chain system will be built into each machine for transaction purposes. Well, that's the way I envisage the monetary setup working. The multiplying effect (for both companies) could be enormous.

PS: TFS is a mult billion dollar co who spend billions on R&D. Its not mates rates. And, yes, we own the licensing rights to OmniCAR. Its called collaboration for a reason.